Comparing COVID-19 Vaccines

 

Vaccine	Country of origin	Doses, interval	Efficacy
Pfizer–BioNTech	United States, Germany	2 doses 3–4 weeks	Overall efficacy was 52% after first dose and 95% after second dose.
Sputnik V	Russia	2 doses 3 weeks	91.6% efficacy.
Oxford–AstraZeneca	United Kingdom, Sweden	2 doses 4–12 weeks	A single standard dose of vaccine provided 76% protection. Efficacy reached 82.4% after a second dose in those with a dosing interval of 12 weeks or more. If the two doses were given less than six weeks apart, the efficacy was only 54.9%. And overall efficacy was 70%, ranging from 62% to 90% with different dosing regimens.
Sinopharm BBIBP-CorV	China	2 doses 3–4 weeks	79.3% efficacy.
CoronaVac Sinovac	China	2 doses 2 weeks	50.4% effective at preventing severe and mild COVID-19 in the late-stage Brazilian trials.
Moderna	United States	2 doses 4 weeks	Overall efficacy of 94.1%, including against severe disease.
Johnson & Johnson	United States, Netherlands	1 dose	Overall efficacy in preventing Covid-19 cases that produced symptoms was 66.1%.
Convidicea (Ad5-nCoV)	China	1 dose	An efficacy of 65.7% against moderate cases of COVID-19 and 90.98% efficacy against severe cases.
EpiVacCorona	Russia	2 doses 3–4 weeks	“100% effective” in early-stage trials.
COVAXIN (BBV152)	India	2 doses 4 weeks	Interim clinical efficacy of 81%.
CoviVac	Russia	2 doses 2 weeks	Granted approval before seeing any late-stage trial results.

Some side effects to a vaccine are usually mild, including mild-to-moderate pain, flushed skin, swelling at the injection site, fatigue, headache and a bit of a temperature.